ArticleCytoJournal2026
Topoisomerase II binding protein 1-interacting checkpoint and replication regulator promotes lung adenocarcinoma proliferation by regulating myelocytomatosis oncogene signaling pathway.
Article in CytoJournal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aims to investigate the role of topoisomerase II binding protein 1-interacting checkpoint and replication regulator (TICRR) on the proliferation of lung adenocarcinoma (LUAD) and its potential molecular mechanism as well as to provide a new strategy to improve LUAD treatment. Material and Methods: The expression level of TICRR in patients with LUAD was analyzed on the basis of the Cancer Genome Atlas program database, and loss- and gain-of-function experiments were conducted to validate whether TICRR promoted the proliferation of LUAD cells. Then, pathway enrichment analysis and luciferase reporter assays were performed to dissect the potential mechanism. Results: Overexpression of TICRR in patients with LUAD was associated with poor survival ( Conclusion: TICRR plays a critical role in fostering the progression of LUAD by regulating the MYC signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.